187 related articles for article (PubMed ID: 30686676)
1. PLX-PAD Cell Treatment of Critical Limb Ischaemia: Rationale and Design of the PACE Trial.
Norgren L; Weiss N; Nikol S; Hinchliffe RJ; Lantis JC; Patel MR; Reinecke H; Ofir R; Rosen Y; Peres D; Aberman Z
Eur J Vasc Endovasc Surg; 2019 Apr; 57(4):538-545. PubMed ID: 30686676
[TBL] [Abstract][Full Text] [Related]
2. PACE: randomized, controlled, multicentre, multinational, phase III study of PLX-PAD for critical limb ischaemia in patients unsuitable for revascularization: randomized clinical trial.
Norgren L; Weiss N; Nikol S; Lantis JC; Patel MR; Hinchliffe RJ; Reinecke H; Volk HD; Reinke P; Fadini GP; Ofir R; Rothenstein D; Halevy N; Karagjozov M; Rundback JH
Br J Surg; 2024 Jan; 111(2):. PubMed ID: 38294084
[TBL] [Abstract][Full Text] [Related]
3. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia.
Losordo DW; Kibbe MR; Mendelsohn F; Marston W; Driver VR; Sharafuddin M; Teodorescu V; Wiechmann BN; Thompson C; Kraiss L; Carman T; Dohad S; Huang P; Junge CE; Story K; Weistroffer T; Thorne TM; Millay M; Runyon JP; Schainfeld R;
Circ Cardiovasc Interv; 2012 Dec; 5(6):821-30. PubMed ID: 23192920
[TBL] [Abstract][Full Text] [Related]
4. Rationale and design of the SAIL trial for intramuscular injection of allogeneic mesenchymal stromal cells in no-option critical limb ischemia.
Wijnand JGJ; Teraa M; Gremmels H; van Rhijn-Brouwer FCC; de Borst GJ; Verhaar MC;
J Vasc Surg; 2018 Feb; 67(2):656-661. PubMed ID: 29242062
[TBL] [Abstract][Full Text] [Related]
5. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia.
Powell RJ; Comerota AJ; Berceli SA; Guzman R; Henry TD; Tzeng E; Velazquez O; Marston WA; Bartel RL; Longcore A; Stern T; Watling S
J Vasc Surg; 2011 Oct; 54(4):1032-41. PubMed ID: 21684715
[TBL] [Abstract][Full Text] [Related]
6. Rationale and design of the MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial investigating autologous bone marrow cell therapy for critical limb ischemia.
Wang SK; Green LA; Motaganahalli RL; Wilson MG; Fajardo A; Murphy MP
J Vasc Surg; 2017 Jun; 65(6):1850-1857.e2. PubMed ID: 28390770
[TBL] [Abstract][Full Text] [Related]
7. Design and rationale of a randomized, double-blind, placebo-controlled phase III study for autologous bone marrow cell transplantation in critical limb ischemia: the BONe Marrow Outcomes Trial in Critical Limb Ischemia (BONMOT-CLI).
Amann B; Lüdemann C; Rückert R; Lawall H; Liesenfeld B; Schneider M; Schmidt-Lucke J
Vasa; 2008 Nov; 37(4):319-25. PubMed ID: 19003741
[TBL] [Abstract][Full Text] [Related]
8. Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients.
Abdul Wahid SF; Ismail NA; Wan Jamaludin WF; Muhamad NA; Abdul Hamid MKA; Harunarashid H; Lai NM
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010747. PubMed ID: 30155883
[TBL] [Abstract][Full Text] [Related]
9. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia.
Belch J; Hiatt WR; Baumgartner I; Driver IV; Nikol S; Norgren L; Van Belle E;
Lancet; 2011 Jun; 377(9781):1929-37. PubMed ID: 21621834
[TBL] [Abstract][Full Text] [Related]
10. Autologous bone marrow mononuclear cell therapy for critical limb ischemia is effective and durable.
Liang TW; Jester A; Motaganahalli RL; Wilson MG; G'Sell P; Akingba GA; Fajardo A; Murphy MP
J Vasc Surg; 2016 Jun; 63(6):1541-5. PubMed ID: 27021379
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Immediate and Long-term Outcomes in Men and Women Undergoing Revascularisation for Chronic Limb Threatening Ischaemia in the Bypass vs. Angioplasty in Severe Ischaemia of the Leg (BASIL-1) Trial.
Benson RA; Meecham LA; Hewitt CA; Bradbury AW
Eur J Vasc Endovasc Surg; 2019 Aug; 58(2):224-228. PubMed ID: 31201136
[TBL] [Abstract][Full Text] [Related]
12. Ethnic minorities with critical limb ischemia derive equal amputation risk reduction from autologous cell therapy compared with whites.
Wang SK; Green LA; Gutwein AR; Drucker NA; Babbey CM; Gupta AK; Fajardo A; Motaganahalli RL; Wilson MG; Murphy MP
J Vasc Surg; 2018 Aug; 68(2):560-566. PubMed ID: 29503004
[TBL] [Abstract][Full Text] [Related]
13. Stem cell and progenitor cell therapy in peripheral artery disease. A critical appraisal.
Lawall H; Bramlage P; Amann B
Thromb Haemost; 2010 Apr; 103(4):696-709. PubMed ID: 20174766
[TBL] [Abstract][Full Text] [Related]
14. Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia.
Iafrati MD; Hallett JW; Geils G; Pearl G; Lumsden A; Peden E; Bandyk D; Vijayaraghava KS; Radhakrishnan R; Ascher E; Hingorani A; Roddy S
J Vasc Surg; 2011 Dec; 54(6):1650-8. PubMed ID: 22019148
[TBL] [Abstract][Full Text] [Related]
15. Bone Marrow derived Cell Therapy in Critical Limb Ischemia: A Meta-analysis of Randomized Placebo Controlled Trials.
Peeters Weem SM; Teraa M; de Borst GJ; Verhaar MC; Moll FL
Eur J Vasc Endovasc Surg; 2015 Dec; 50(6):775-83. PubMed ID: 26460286
[TBL] [Abstract][Full Text] [Related]
16. The impact of isolated tibial disease on outcomes in the critical limb ischemic population.
Gray BH; Grant AA; Kalbaugh CA; Blackhurst DW; Langan EM; Taylor SA; Cull DL
Ann Vasc Surg; 2010 Apr; 24(3):349-59. PubMed ID: 20045628
[TBL] [Abstract][Full Text] [Related]
17. Long-term clinical outcome after intramuscular transplantation of granulocyte colony stimulating factor-mobilized CD34 positive cells in patients with critical limb ischemia.
Kinoshita M; Fujita Y; Katayama M; Baba R; Shibakawa M; Yoshikawa K; Katakami N; Furukawa Y; Tsukie T; Nagano T; Kurimoto Y; Yamasaki K; Handa N; Okada Y; Kuronaka K; Nagata Y; Matsubara Y; Fukushima M; Asahara T; Kawamoto A
Atherosclerosis; 2012 Oct; 224(2):440-5. PubMed ID: 22877866
[TBL] [Abstract][Full Text] [Related]
18. The Relationship Between Obesity and Amputation-free Survival in Patients Undergoing Lower-limb Revascularisation for Chronic Limb-threatening Ischaemia: A Retrospective Cohort Study.
Sabbagh C; Nickinson A; Cullen S; Patel B; Dubkova S; Gray L; Davies R; Sayers R
Ann Vasc Surg; 2022 Jan; 78():288-294. PubMed ID: 34474129
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the Clinical and Histologic Analysis of Mesenchymal Stromal Cells in AmPutations (CHAMP) trial investigating the therapeutic mechanism of mesenchymal stromal cells in the treatment of critical limb ischemia.
Wang SK; Green LA; Drucker NA; Motaganahalli RL; Fajardo A; Murphy MP
J Vasc Surg; 2018 Jul; 68(1):176-181.e1. PubMed ID: 29395424
[TBL] [Abstract][Full Text] [Related]
20. Venous Arterialisation for Salvage of Critically Ischaemic Limbs: A Systematic Review and Meta-Analysis.
Schreve MA; Vos CG; Vahl AC; de Vries JP; Kum S; de Borst GJ; Ünlü Ç
Eur J Vasc Endovasc Surg; 2017 Mar; 53(3):387-402. PubMed ID: 28027892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
